A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets

International Journal of Cancer

Volumn 128, Issue 5, 2011, Pages 1069-1079

  Grade, Marian ^a,b   Hummon, Amanda B ^b   Camps, Jordi ^b   Emons, Georg ^a   Spitzner, Melanie ^a   Gaedcke, Jochen ^a   Hoermann, Patrick ^b   Ebner, Reinhard ^b   Becker, Heinz ^a   Difilippantonio, Michael J ^b   Ghadimi, B Michael ^a   Beissbarth, Tim ^a   Caplen, Natasha J ^b   Ried, Thomas ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

colorectal cancer; functional genomics; RNAi; systems biology; therapeutic targets

Indexed keywords

CDC28 PROTEIN KINASE REGULATOR SUBUNIT 2; HIGH MOBILITY GROUP AT HOOK 1; HISTONE H1; MEMBER RAS ONCOGENE FAMILY; MYC PROTEIN; NUCLEOPROTEIN 5A; ONCOPROTEIN; PLECKSTRIN HOMOLOGY LIKE DOMAIN FAMILY A MEMBER 1; PROTEIN KINASE DNA ACTIVATED CATALYTIC POLYPEPTIDE; RAS PROTEIN; RIBONUCLEOTIDE REDUCTASE M POLYPEPTIDE; RIBOSOME PROTEIN S2; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOSS; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE SILENCING; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; RNA INTERFERENCE;

EID: 78650720162     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25453     Document Type: Article

References (47)

1. Grade M, Ghadimi BM, Varma S, Simon R, Wangsa D, Barenboim-Stapleton L, Liersch T, Becker H, Ried T, Difilippantonio MJ,. Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 2006; 66: 267-82.
2. Grade M, Hormann P, Becker S, Hummon AB, Wangsa D, Varma S, Simon R, Liersch T, Becker H, Difilippantonio MJ, Ghadimi BM, Ried T,. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 2007; 67: 41-56.
3. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001; 98: 8012-7.
4. Martin SE, Caplen NJ,. Mismatched siRNAs downregulate mRNAs as a function of target site location. FEBS Lett 2006; 580: 3694-8.
5. Martin SE, Jones TL, Thomas CL, Lorenzi PL, Nguyen DA, Runfola T, Gunsior M, Weinstein JN, Goldsmith PK, Lader E, Huppi K, Caplen NJ,. Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res 2007; 35: e57.
6. Camps J, Nguyen QT, Padilla-Nash HM, Knutsen T, McNeil NE, Wangsa D, Hummon AB, Grade M, Ried T, Difilippantonio MJ,. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer 2009; 48: 1002-17.
7. Frohlich H, Speer N, Poustka A, Beissbarth T,. GOSim-an R-package for computation of information theoretic GO similarities between terms and gene products. BMC Bioinformatics 2007; 8: 166.
8. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR,. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009; 4: e6146.
9. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12: 1294-300.
10. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr, Marks JR, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7.
11. Meyer N, Penn LZ,. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-90.
12. Doench JG, Sharp PA,. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18: 504-11.
13. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R,. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20: 515-24.
14. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR,. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-9.
15. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS,. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12: 1179-87.
16. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D, Karpilow J, Marshall WS, Khvorova A,. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006; 12: 988-93.
17. Frohlich H, Beissbarth T, Tresch A, Kostka D, Jacob J, Spang R, Markowetz F,. Analyzing gene perturbation screens with nested effects models in R and bioconductor. Bioinformatics 2008; 24: 2549-50.
18. Frohlich H, Fellmann M, Sultmann H, Poustka A, Beissbarth T,. Estimating large-scale signaling networks through nested effect models with intervention effects from microarray data. Bioinformatics 2008; 24: 2650-6.
19. Nordlund P, Reichard P,. Ribonucleotide reductases. Annu Rev Biochem 2006; 75: 681-706.
20. Cleynen I, Van de Ven WJ,. The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008; 32: 289-305.
21. Schwartz B, Algamas-Dimantov A, Hertz R, Nataf J, Kerman A, Peri I, Bar-Tana J,. Inhibition of colorectal cancer by targeting hepatocyte nuclear factor-4alpha. Int J Cancer 2009; 124: 1081-9.
22. Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL,. Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005; 11: 2612-9. (Pubitemid 40569461)
23. Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME,. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 2007; 13: 2207-15.
24. Bartlett DW, Davis ME,. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 2007; 97: 909-21.
25. Strebhardt K, Ullrich A,. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-30.
26. Ripani E, Sacchetti A, Corda D, Alberti S,. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76: 671-6.
27. Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, Alberti S,. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 1995; 62: 610-8.
28. Wang J, Day R, Dong Y, Weintraub SJ, Michel L,. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008; 7: 280-5.
29. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON,. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 2008; 105: 20882-7.
30. Truong A, Feng N, Sayegh D, Mak B, Hahn S, Pereira D, Young D,. AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy. 99th AACR Annual Meeting Abstract #3990; 2008.
31. Fusco A, Fedele M,. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7: 899-910.
32. Hayano T, Yanagida M, Yamauchi Y, Shinkawa T, Isobe T, Takahashi N,. Proteomic analysis of human Nop56p-associated pre-ribosomal ribonucleoprotein complexes. Possible link between Nop56p and the nucleolar protein treacle responsible for Treacher Collins syndrome. J Biol Chem 2003; 278: 34309-19.
33. Swiercz R, Person MD, Bedford MT,. Ribosomal protein S2 is a substrate for mammalian PRMT3 (protein arginine methyltransferase 3). Biochem J 2005; 386: 85-91.
34. Kowalczyk P, Woszczynski M, Ostrowski J,. Increased expression of ribosomal protein S2 in liver tumors, posthepactomized livers, and proliferating hepatocytes in vitro. Acta Biochim Pol 2002; 49: 615-24.
35. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J,. Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol 2007; 377: 203-22.
36. Wang M, Hu Y, Stearns ME,. RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res 2009; 28: 6.
37. Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, Tan YL, Loh MC, Hew CL, Shah N, Druker BJ, Chong PK, et al. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 2007; 6: 2072-87.
38. Prochownik EV,. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004; 4: 289-302.
39. Wu CH, Sahoo D, Arvanitis C, Bradon N, Dill DL, Felsher DW,. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet 2008; 4: e1000090.
40. Shiio Y, Donohoe S, Yi EC, Goodlett DR, Aebersold R, Eisenman RN,. Quantitative proteomic analysis of Myc oncoprotein function. EMBO J. 2002; 21: 5088-96.
41. Koch HB, Zhang R, Verdoodt B, Bailey A, Zhang CD, Yates JR, 3rd, Menssen A, Hermeking H,. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell Cycle 2007; 6: 205-17.
42. Chen Y, Blackwell TW, Chen J, Gao J, Lee AW, States DJ,. Integration of genome and chromatin structure with gene expression profiles to predict c-MYC recognition site binding and function. PLoS Comput Biol 2007; 3: e63.
43. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, Monnot C, Germain S,. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006; 103: 18721-6.
44. Seraj MJ, Samant RS, Verderame MF, Welch DR,. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000; 60: 2764-9.
45. Villalonga P, Guasch RM, Riento K, Ridley AJ,. RhoE inhibits cell cycle progression and Ras-induced transformation. Mol Cell Biol 2004; 24: 7829-40.
46. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW, Brown TJ,. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res 2005; 65: 6139-50.
47. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, et al. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 2008; 27: 7192-200.